0001225208-20-004163.txt : 20200303
0001225208-20-004163.hdr.sgml : 20200303
20200303161502
ACCESSION NUMBER: 0001225208-20-004163
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200228
FILED AS OF DATE: 20200303
DATE AS OF CHANGE: 20200303
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Nanavaty Maulik
CENTRAL INDEX KEY: 0001529708
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-11083
FILM NUMBER: 20682401
MAIL ADDRESS:
STREET 1: BOSTON SCIENTIFIC CORPORATION
STREET 2: 300 BOSTON SCIENTIFIC WAY
CITY: MARLBOROUGH
STATE: MA
ZIP: 01752-1234
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BOSTON SCIENTIFIC CORP
CENTRAL INDEX KEY: 0000885725
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 042695240
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 300 BOSTON SCIENTIFIC WAY
CITY: MARLBOROUGH
STATE: MA
ZIP: 01752-1234
BUSINESS PHONE: 508-683-4000
MAIL ADDRESS:
STREET 1: 300 BOSTON SCIENTIFIC WAY
CITY: MARLBOROUGH
STATE: MA
ZIP: 01752-1234
4
1
doc4.xml
X0306
4
2020-02-28
0000885725
BOSTON SCIENTIFIC CORP
BSX
0001529708
Nanavaty Maulik
300 BOSTON SCIENTIFIC WAY
MARLBOROUGH
MA
01752-1234
1
SVP & Pres, Neuromodulation
Common Stock
2020-02-28
4
M
0
1629.0000
0.0000
A
267539.0000
D
Common Stock
2020-02-28
4
F
0
808.0000
37.3900
D
266731.0000
D
Common Stock
2020-03-02
4
M
0
9623.0000
16.3100
A
276354.0000
D
Common Stock
2020-03-02
4
S
0
16763.0000
37.4744
D
259591.0000
D
Deferred Stock Units
2020-02-28
4
M
0
1629.0000
0.0000
D
2022-02-28
Common Stock
1629.0000
3259.0000
D
Stock Option (Right to Buy)
16.3100
2020-03-02
4
M
0
9623.0000
0.0000
D
2025-02-23
Common Stock
9623.0000
0.0000
D
Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.
This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.
Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $37.35 to $37.655, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant.
Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant.
/s/ Scott G. Hodgdon, Attorney-in-Fact
2020-03-03